72
Participants
Start Date
September 18, 2012
Primary Completion Date
March 31, 2018
Study Completion Date
September 30, 2019
PAZOPANIB treatment
"Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum"
Active Comparator: Vinblastine and Methotrexate
Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
Institut Bergonié, Bordeaux
Lead Sponsor
Institut Bergonié
OTHER